AZD1390

Name: AZD1390
Brand: MedChemExpress
SKU: HY-109566
Rating: 5.0 (9 reviews)

製品番号: HY-109566 純度: 99.22%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant ATM inhibitor with an IC₅₀ of 0.78 nM in cell.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 2089288-03-7

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 210	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 210	在庫あり	Estimated Time of Arrival: December 31
Solid
1 mg	$100	在庫あり	Estimated Time of Arrival: December 31
5 mg	$200	在庫あり	Estimated Time of Arrival: December 31
10 mg	$290	在庫あり	Estimated Time of Arrival: December 31
25 mg	$590	在庫あり	Estimated Time of Arrival: December 31
50 mg	$750	在庫あり	Estimated Time of Arrival: December 31
100 mg	$960	在庫あり	Estimated Time of Arrival: December 31
200 mg		お問い合わせ
500 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 9 publication(s) in Google Scholar

顧客検証

Cell Imaging/Staining

Others

In Vivo Efficacy Study

: AZD1390 purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Jun 13;10(1):185. [Abstract]; Immunoblot analysis was performed on cell lysates extracted from ANV5-OE cells at different time points after treatment with IR (2 Gy), IR/ENPP1i (5 µM), IR/ATMi (AZD1390: 5 µM), or triple therapy to detect the protein expression levels of γHA2X, PARP1, cleaved PARP1 (c-PARP), ENPP1, RAD51, GAPDH, and Tubulin.

: AZD1390 purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Jun 13;10(1):185. [Abstract]; The number of positive cells labeled with anti-γH2AX antibody was quantitatively assessed. Cells were incubated with ENPP1i (5 µM) and ATMi (AZD1390: 5 µM) for 24 h.

: AZD1390 purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Jun 13;10(1):185. [Abstract]; After orthotopic transplantation of OE-ANV5 cells, mice were treated with FD (6.2 Gy × 4) alone, or in combination with ENPP1i (6 mg/kg, twice daily), ATMi (AZD1390: 5 mg/kg, once daily), or triple therapy (n = 8 mice per group), and changes in tumor volume were observed.

: AZD1390 purchased from MedChemExpress. Usage Cited in: EMBO J. 2023 Mar 15;42(6):e112094. [Abstract]; HeLa cells expressing Flag‐tagged VDAC2 and V5‐tagged ANT2 were subjected to Co‐IP using anti‐Flag antibody and analyzed by western blot as indicated. ANT2, but not VDAC2, temporarily dissociated from DNA‐PKcs after treatment of 10 Gy IR. ATM knockdown and inhibition (AZD1390, 10 nM) disrupted the dissociation.

: AZD1390 purchased from MedChemExpress. Usage Cited in: EMBO J. 2023 Mar 15;42(6):e112094. [Abstract]; Primary mouse embryonic fibroblasts (MEF) RPE-1 were analyzed for ADP-ATP exchange activity at different time points (up to 16 hours) in response to 100 μM H₂O₂. The ATM inhibitor (AZD1390, 10 nM) was also included in the parallel analysis.

ATM/ATR アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

ATM ATR TRRAP

生物活性
プロトコル
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant ATM inhibitor with an IC₅₀ of 0.78 nM in cell^[1].

IC₅₀ & Target^[1]

ATM

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	> 20 3 Compound: AZD1390	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
A549	IC₅₀	43 3 Compound: AZD1390	Antiproliferative activity against ATM-proficient human A549 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against ATM-proficient human A549 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 36462444]
HT-29	IC₅₀	> 10 3 Compound: AZD1390	Cytotoxicity against ATM proficient human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against ATM proficient human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35183872]
HCT-116	IC₅₀	10.5 3 Compound: AZD1390	Antiproliferative activity against ATM-proficient human HCT-116 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against ATM-proficient human HCT-116 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 36462444]
A549	IC₅₀	43 3 Compound: AZD1390	Antiproliferative activity against ATM-proficient human A549 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against ATM-proficient human A549 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 36462444]
COLO 205	IC₅₀	> 20 3 Compound: AZD1390	Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
HT-29	IC₅₀	>30 3 Compound: AZD1390	Antiproliferative activity against ATM-proficient human HT-29 cells assessed as reduction in cell proliferation incubated for 3 days by MTT assay Antiproliferative activity against ATM-proficient human HT-29 cells assessed as reduction in cell proliferation incubated for 3 days by MTT assay	[PMID: 36462444]
HT-29	IC₅₀	>10 3 Compound: AZD1390	Antiproliferative activity against human HT-29 cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HT-29 cells incubated for 72 hrs by CCK-8 assay	[PMID: 37130473]
HCT-116	IC₅₀	10.5 3 Compound: AZD1390	Antiproliferative activity against ATM-proficient human HCT-116 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against ATM-proficient human HCT-116 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 36462444]
HT-29	IC₅₀	>10 3 Compound: AZD1390	Cytotoxicity against ATM proficient human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against ATM proficient human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35183872]
HCT-116	IC₅₀	> 20 3 Compound: AZD1390	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
HT-29	IC₅₀	> 10 3 Compound: AZD1390	Cytotoxicity against ATM proficient human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against ATM proficient human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35183872]
HT-29	IC₅₀	> 10 3 Compound: AZD1390	Antiproliferative activity against human HT-29 cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HT-29 cells incubated for 72 hrs by CCK-8 assay	[PMID: 37130473]
HT-29	IC₅₀	> 30 3 Compound: AZD1390	Antiproliferative activity against ATM-proficient human HT-29 cells assessed as reduction in cell proliferation incubated for 3 days by MTT assay Antiproliferative activity against ATM-proficient human HT-29 cells assessed as reduction in cell proliferation incubated for 3 days by MTT assay	[PMID: 36462444]
K562	IC₅₀	> 20 3 Compound: AZD1390	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
LoVo	IC₅₀	> 20 3 Compound: AZD1390	Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
NCI-H358	IC₅₀	> 20 3 Compound: AZD1390	Cytotoxicity against human NCI-H358 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human NCI-H358 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
RKO	IC₅₀	> 20 3 Compound: AZD1390	Cytotoxicity against human RKO cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human RKO cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
SW-620	IC₅₀	> 20 3 Compound: AZD1390	Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
SW13	IC₅₀	> 20 3 Compound: AZD1390	Cytotoxicity against human SW13 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SW13 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
SW480	IC₅₀	> 20 3 Compound: AZD1390	Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]

体内実験

Median survival of mice treated with AZD1390 and radiation are significantly longer than untreated control mice (p=0.001). No overt signs of treatment toxicity are observed with small animal radiation research platform (SARRP) contrary to wholehead irradiated mice that seem to develop mucositis and difficulties drinking and eating at doses >10 Gy in combination with AZD1390^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

分子量

477.57

分子式

C₂₇H₃₂FN₅O₂

CAS 番号

2089288-03-7

Appearance

Solid

Color

White to off-white

SMILES

O=C(N1C(C)C)N(C)C2=C1C3=CC(C4=CC=C(OCCCN5CCCCC5)N=C4)=C(F)C=C3N=C2

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 5 mg/mL (10.47 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.0939 mL	10.4697 mL	20.9393 mL
5 mM	0.4188 mL	2.0939 mL	4.1879 mL
10 mM	0.2094 mL	1.0470 mL	2.0939 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 5 mg/mL (10.47 mM); Suspended solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 5 mg/mL (10.47 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

純度とドキュメンテーション

純度: 99.22%

Select Batch:

データシート (274 KB) SDS (393 KB)

COA (247 KB) HNMR (201 KB) LCMS (95 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Durant ST, et al. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv. 2018 Jun 20;4(6):eaat1719. [Content Brief]

[2]. J. Kahn, et al. Next-Generation ATM Kinase Inhibitors Under Development Radiosensitize Glioblastoma With Conformal Radiation in a Mouse Orthotopic Model. IJROBP. 2017. 99, 600-601.

動物実験
^[2]

Mouse GL261 glioma (p53 mutant) cells are implanted intra-cranially into immunocompetent, syngeneic C57/bl6 mice followed by bioluminescent imaging (BLI) prior to randomization. AZD1390 is administered by oral gavage prior to deliver multiple fractions of 2-3 Gy of radiation on 2 to 4 consecutive days. Radiation is administered via small animal radiation research platform (SARRP) irradiation to the site of the tumor with a 5×5 mm lateral ﬁeld^[2].

MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。

参考文献

[1]. Durant ST, et al. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv. 2018 Jun 20;4(6):eaat1719. [Content Brief]

[2]. J. Kahn, et al. Next-Generation ATM Kinase Inhibitors Under Development Radiosensitize Glioblastoma With Conformal Radiation in a Mouse Orthotopic Model. IJROBP. 2017. 99, 600-601.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.0939 mL	10.4697 mL	20.9393 mL	52.3483 mL
	5 mM	0.4188 mL	2.0939 mL	4.1879 mL	10.4697 mL
	10 mM	0.2094 mL	1.0470 mL	2.0939 mL	5.2348 mL

AZD1390 Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

AZD13902089288-03-7AZD 1390AZD-1390ATM/ATRAtaxia telangiectasia mutatedATM and RAD3 relatedInhibitorinhibitorinhibit

最近チェックした製品:

製品名

カスタマ需要量 *

お名前 *

タイトル

メールアドレス *

電話番号 *

デパートメント

組纖名 *

市区町村

都道府県

国或いは地域 *

必ず会社名を記載ください。個人への返信は行いません。

備考

製品名

Lot #

お名前 *

メールアドレス *

電話番号 *

部門 *

組纖名 *

国或いは地域 *

備考

AZD1390

カスタマーレビュー

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

ATM/ATR アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

AZD1390 Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

AZD1390

カスタマーレビュー

AZD1390 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

ATM/ATR アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

AZD1390 Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report